Skip to main content

4D Molecular Therapeutics

4D Molecular Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on genetic medicines. The company develops targeted adeno-associated virus gene therapy product candidates using its proprietary Therapeutic Vector Evolution platform. Main revenue drivers currently stem from strategic development collaborations, licensing agreements, and capital markets financing as pipeline candidates advance through clinical trials. 4D Molecular Therapeutics targets patients with severe genetic diseases in ophthalmology, pulmonology, and cardiology across North America and international markets. The company holds a pioneer position in directed evolution vector discovery for targeted tissue delivery of genetic medicines. Headquartered in Emeryville, California, 4D Molecular Therapeutics Inc is listed on the Nasdaq Stock Market.

2 of the funds FundTelligence covers report a position in 4D Molecular Therapeutics.

Legal name
4D Molecular Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
2
Exposure themes
Gene Therapy, Genetic Medicine, Precision Medicine & Genomics

Funds holding 4D Molecular Therapeutics

Loading...